Protocol Library - Altai Oncology Software

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions

Over 1,000 cancer treatment protocols

Medical Oncology, Hematology, Bone Marrow Transplantation

With administration details, lab parameters, indications, and summarized references

Updated monthly to include latest approvals and major papers

Reviewed by Medical Oncologists and Hematologists

Acute myeloid leukemia

New Drug: Enasidenib for IDH2 Mutant AML

Ulas D. Bayraktar, MD

Biliary Tract Cancer

New Protocol: Pembrolizumab with CISplatin and Gemcitabine in Metastatic Biliary Tract Cancer

Ulas D. Bayraktar, MD

Ovarian Cancer

New Drug: Mirvetuximab Soravtansine in Advanced Ovarian Cancer

Ulas D. Bayraktar, MD

GastroEsophageal Cancer

New Reference: DOCEtaxel, OXALIplatin, Capecitabine in Locally Advanced Gastric Cancer

Ulas D. Bayraktar, MD

Prostate Cancer

New Reference: Enzalutamide in Recurrent Prostate Cancer

Ulas D. Bayraktar, MD

Chronic Lymphocytic Leukemia

New Indication: Pirtobrutinib in CLL

Ulas D. Bayraktar, MD

Biliary Tract Cancer

New Indication: Trastuzumab plus CISplatin-Gemcitabine in Biliary Tract Cancers

Ulas D. Bayraktar, MD

Non-Small Cell Lung Cancer

New Indication: Osimertinib in First-Line NSCLC

Ulas D. Bayraktar, MD

Thyroid Cancer

New Drug: Selpercatinib in RET-mutant Medullary Thyroid Cancer

Ulas D. Bayraktar, MD

Acute myeloid leukemia

New Drug: Enasidenib for IDH2 Mutant AML

International, multicenter, randomized, open-label, phase 3 trial Age ≥60 years, IDH2 gene mutated, de novo or secondary AML Previously 2 or 3 prior AML- directed therapies Enasi

Biliary Tract Cancer

New Protocol: Pembrolizumab with CISplatin and Gemcitabine in Metastatic Biliary Tract Cancer

Phase III, double-blind, randomized, controlled, multicenter, open-label trial (KEYNOTE-966) Previously untreated, unresectable, locally advanced or metastatic biliary tract cancer

New Drug: Mirvetuximab Soravtansine in Advanced Ovarian Cancer

A Phase III, Randomized, Open-label trial (MIRASOL) Platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate recep

GastroEsophageal Cancer

New Reference: DOCEtaxel, OXALIplatin, Capecitabine in Locally Advanced Gastric Cancer

Randomized, open-label, phase 3 trial Potentially resectable, locally advanced cT3-4 gastric adenocarcinoma in patients younger than 60 years Neoadjuvant Docetaxel, Oxaliplatin, Ca

Prostate Cancer

New Reference: Enzalutamide in Recurrent Prostate Cancer

Phase 3, randomized, international trial (EMBARK)) Adult patients with prostate cancer who had biochemical recurrence after local therapy and meet the following criteria at screeni

Chronic Lymphocytic Leukemia

New Indication: Pirtobrutinib in CLL

Open-label, multi-center Phase 1/2 study (BRUIN) Relapse/Refractory CLL/SLL who had previously received a BTK inhibitor Pirtobrutinib (n=317)

Biliary Tract Cancer

New Indication: Trastuzumab plus CISplatin-Gemcitabine in Biliary Tract Cancers

Investigator-initiated, open-label, single-arm, multi-institutional, phase II trial (TAB) Adult patients with HER2-positive, treatment-naïve BTCs Trastuzumab + Gemcitabine + Cispl

Non-Small Cell Lung Cancer

New Indication: Osimertinib in First-Line NSCLC

Multi-center, phase 2 nonrandomized clinical trial (UNICORN) Previously untreated patients with metastatic NSCLC harboring uncommon EGFR mutations, excluding exon 20 insertion muta

New Drug: Selpercatinib in RET-mutant Medullary Thyroid Cancer

Phase 3, randomized trial (LIBRETTO-531) RET mutant, unresectable, locally advanced or metastatic medullary thyroid cancer and no history of treatment with kinase inhibitors Selpe

Our Solutions

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols

Altai Oncology Suite

Our premiere, CE-marked, Windows application designed for cancer centers

Altai Oncology App

Easiest access to our protocol library on your hands

Altai Chemo Planner

Core features of Altai Oncology Suite for the solo Oncologist/Hematologist

Articles

Computerized Chemotherapy Order Entry

The Power of a Protocol Library: Standardizing Oncology Care Across Institutions

Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …

From Protocol to Pharmacy: Ensuring Seamless Chemotherapy Order Handover

Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.

Back to top Drag